You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
PROPEL™ sinus implants feature an innovative 2-in-1 mechanism that maintains the surgical opening following sinus surgery while delivering mometasone furoate, a potent corticosteroid, directly to the sinus mucosa where it is needed1-3.
Mometasone furoate was selected for use in PROPEL™ implant for its sinonasal drug characteristics7:
Highly lipophilic - Readily absorbs into tissue
Targeted + potent - High glucocorticoid receptor affinity
Low systemic bioavailability - Minimizes systemic effects
Drug characteristics comparison6-9
* Lipophilicity numbers normalized relative to triamcinolone acetonide.
† As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.
‡ As measured by plasma concentration of drug from intranasal vs intravenous route.
PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
PROPEL™ Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
PROPEL™ Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy. 2009;23(6):591-596.
Murr AH,et al. Int Forum Allergy Rhinol. 2011;1:23–32. REF-10007.
Lemke T, Williams D, Roche V, Zito SW, eds. Foye’s Principles of Medicinal Chemistry. 6th ed. Balitmore, MD: Lippincott Williams & Wilkins; 2008.
Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356-363.
Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1-12.
PubChem. Dexamethasone. https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone. Accessed June 24, 2019.
UC202311003EE MPM – 12526 Rev. 1.0
CRS, chronic rhinosinusitis; MF, mometasone furoate.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu
PROPEL™ Important Safety Information:
The PROPEL™ sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL™ for the ethmoid sinus, PROPEL™ Mini for the ethmoid sinus/frontal sinus opening, and PROPEL™ Contour for the frontal sinus ostia in chronic rhinosinusitis patients. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.intersectENT.co.uk. For use by healthcare professionals only.
Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.
PROPEL™ and PROPEL™ Mini: